Expression of prostate specific molecules in Bacille Calmette-Guerin: An immunotherapeutic approach to prostate cancer

C. D. Zeoli; M. Maitland; H. Rose; B. Bloom; A. Mittelman; J. Geliebter

doi:10.1046/j.1525-1411.2001.32002.x

Expression of prostate specific molecules in Bacille Calmette-Guerin: An immunotherapeutic approach to prostate cancer

C. D. Zeoli, M. Maitland, H. Rose, B. Bloom, A. Mittelman, J. Geliebter

Pathology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.

Original language	English (US)
Pages (from-to)	92-97
Number of pages	6
Journal	Prostate Journal
Volume	3
Issue number	2
DOIs	https://doi.org/10.1046/j.1525-1411.2001.32002.x
State	Published - 2001

ASJC Scopus subject areas

Oncology
Urology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1046/j.1525-1411.2001.32002.x

Cite this

@article{3b5ae1e9e65246ba956c9a89f060080b,

title = "Expression of prostate specific molecules in Bacille Calmette-Guerin: An immunotherapeutic approach to prostate cancer",

abstract = "Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.",

author = "Zeoli, {C. D.} and M. Maitland and H. Rose and B. Bloom and A. Mittelman and J. Geliebter",

year = "2001",

doi = "10.1046/j.1525-1411.2001.32002.x",

language = "English (US)",

volume = "3",

pages = "92--97",

journal = "Prostate Journal",

issn = "1095-5100",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Expression of prostate specific molecules in Bacille Calmette-Guerin

T2 - An immunotherapeutic approach to prostate cancer

AU - Zeoli, C. D.

AU - Maitland, M.

AU - Rose, H.

AU - Bloom, B.

AU - Mittelman, A.

AU - Geliebter, J.

PY - 2001

Y1 - 2001

N2 - Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.

AB - Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035715916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035715916&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1411.2001.32002.x

DO - 10.1046/j.1525-1411.2001.32002.x

M3 - Article

AN - SCOPUS:0035715916

SN - 1095-5100

VL - 3

SP - 92

EP - 97

JO - Prostate Journal

JF - Prostate Journal

IS - 2

ER -

Expression of prostate specific molecules in Bacille Calmette-Guerin: An immunotherapeutic approach to prostate cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this